The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

ILMOFOSINE     2-[[2- (hexadecylsulfanylmethyl)-3- methoxy...

Synonyms: Ilmofosina, Ilmofosinum, CHEMBL28930, I2409_SIGMA, NSC-601679, ...
This record was replaced with 55009.
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NCI60_004534

  • CONCLUSIONS: The dose-limiting toxicity of ilmofosine is gastrointestinal and the recommended dose for Phase II trials is 450 mg/m(2) as a 2-h weekly infusion [1].
  • A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma [2].
  • The activity of the alkyllysophospholipids Et-18-OCH3 and BM 41.440 and of the alkylphosphocholine He-PC was investigated in a human glioma xenograft (T 406) [3].
  • Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells [4].
  • The activity of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18OMe) and 3-hexadecylmercapto-2-methoxymethyl-propyl-1-phosphocholine (Ilmofosine) (BM 41.440) was tested in variants of B16 murine melanoma, grown in adhesion cultures (B16F1 with low metastatic potential; B16F10 and B16BL6 with high metastatic potential) [5].

Psychiatry related information on NCI60_004534

  • In a Phase I trial of a weekly 2 hour infusion schedule of ilmofosine, a syndrome of lethargy, diminished performance status, and mild hepatotoxicity was dose-limiting at 550 mg/m2 [6].

High impact information on NCI60_004534

  • Myosin light chain kinase and cAMP-dependent protein kinase were not inhibited by BM 41.440, indicating a specificity of the action of the agent [7].
  • BM 41.440 partly blocked the TPA-induced depletion of soluble PKC in HL60 and KG-1 cells (responsive to the differentiating effect of TPA) but not in K562 cells (resistant to the TPA effect) [7].
  • Plasma concentrations of ilmofosine and its sulfoxide metabolite were evaluated by high-pressure liquid chromatography [1].
  • Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth [8].
  • No association between the expression of the MDR2-encoded P-gp and resistance to ilmofosine was observed [9].

Biological context of NCI60_004534


Anatomical context of NCI60_004534


Associations of NCI60_004534 with other chemical compounds


Gene context of NCI60_004534


Analytical, diagnostic and therapeutic context of NCI60_004534


  1. Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors. Giantonio, B.J., Derry, C., McAleer, C., McPhillips, J.J., O'Dwyer, P.J. Clin. Cancer Res. (2004) [Pubmed]
  2. A phase II trial of ilmofosine in non-small cell bronchogenic carcinoma. Woolley, P.V., Schultz, C.J., Rodriguez, G.I., Gams, R.A., Rowe, K.W., Dadey, M.L., Von Hoff, D.D., McPhillips, J.J. Investigational new drugs. (1996) [Pubmed]
  3. Interstitial chemotherapy of experimental gliomas. Zeller, W.J., Bauer, S., Remmele, T., Wowra, B., Sturm, V., Stricker, H. Cancer Treat. Rev. (1990) [Pubmed]
  4. Cytotoxicity of ether phospholipid BM 41.440 on neuroblastoma cells. Girgert, R., Schweizer, P., Bock, I., Narr, R., Bruchelt, G. J. Cancer Res. Clin. Oncol. (1995) [Pubmed]
  5. Effect of cell density on cytotoxicity of ether lipid analogues in variants of B16 murine melanoma. Trulla, L.L., Magistrelli, A., Salmona, M., Tacconi, M.T. Lipids (1993) [Pubmed]
  6. Phase I trial of ilmofosine as a 24 hour infusion weekly. von Mehren, M., Giantonio, B.J., McAleer, C., Schilder, R., McPhillips, J., O'Dwyer, P.J. Investigational new drugs. (1995) [Pubmed]
  7. Effects of thioether phospholipid BM 41.440 on protein kinase C and phorbol ester-induced differentiation of human leukemia HL60 and KG-1 cells. Shoji, M., Raynor, R.L., Berdel, W.E., Vogler, W.R., Kuo, J.F. Cancer Res. (1988) [Pubmed]
  8. Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth. Bittman, R., Byun, H.S., Reddy, K.C., Samadder, P., Arthur, G. J. Med. Chem. (1997) [Pubmed]
  9. Resistance to the new anti-cancer phospholipid ilmofosine (BM 41 440). Hofmann, J., Utz, I., Spitaler, M., Hofer, S., Rybczynska, M., Beck, W.T., Herrmann, D.B., Grunicke, H. Br. J. Cancer (1997) [Pubmed]
  10. The protein kinase C inhibitor ilmofosine (BM 41 440) arrests cells in G2 phase and suppresses CDC2 kinase activation through a mechanism different from that of DNA damaging agents. Hofmann, J., O'Connor, P.M., Jackman, J., Schubert, C., Ueberall, F., Kohn, K.W., Grunicke, H. Biochem. Biophys. Res. Commun. (1994) [Pubmed]
  11. Role of protein kinase C in ras-mediated fos-expression. Uberall, F., Kampfer, S., Schubert, C., Doppler, W., Grunicke, H.H. Adv. Enzyme Regul. (1994) [Pubmed]
  12. Pharmacokinetics of the thioether phospholipid analogue BM 41.440 in rats. Herrmann, D.B., Besenfelder, E., Bicker, U., Pahlke, W., Böhm, E. Lipids (1987) [Pubmed]
  13. Influence of probes for calcium-calmodulin and protein kinase C signalling on the plasma membrane Ca2+-ATPase activity of rat synaptosomes and leukocyte membranes. Grosman, N. Immunopharmacology (1998) [Pubmed]
  14. Effect of the anti-neoplastic agents edelfosine (ET-18-OCH3), ilmofosine (BM 41.440) and the hexadecylphosphocholine analogues D-20133 and D-21266 on histamine release from isolated rat mast cells. Grosman, N. Immunopharmacology (1999) [Pubmed]
  15. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. Croft, S.L., Snowdon, D., Yardley, V. J. Antimicrob. Chemother. (1996) [Pubmed]
  16. In vitro and in vivo cytotoxicity of alkyl lysophospholipid ET-18-OCH3 and thioether lipid BM 41.440. Leder, G.H., Fiebig, H.H., Wallbrecher, E., Winterhalter, B.R., Löhr, G.W. Lipids (1987) [Pubmed]
  17. BM 41.440: a new antineoplastic, antimetastatic, and immune-stimulating drug. Herrmann, D.B., Bicker, U., Pahlke, W. Cancer detection and prevention. Supplement : official publication of the International Society for Preventive Oncology, Inc. (1987) [Pubmed]
WikiGenes - Universities